Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “pd-”

81 pharma patents match "pd-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 81
Index total 30,257
Page 1 / 4

Quick answer

This filtered view shows 81 pharmaceutical patents matching "pd-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

81 results for “pd-” · 30,257 patents in full index Clear search

  1. WO 2026107143

    COMBINAISON DE DOSES FIXES D'ANTICORPS ANTI-FUCOSYL-GM1 ET D'ANTICORPS ANTI-PD-1 ET SES UTILISATIONS

    BRISTOL MYERS SQUIBB CO [US] · Granted May 21, 2026 · Expires May 16, 2046

    granted
  2. WO 2026057739

    POLYTHÉRAPIE COMPRENANT DES ANTICORPS ANTI-CTLA4 ET DES ANTICORPS ANTI-PD-1 POUR LE TRAITEMENT DU CANCER DE L'OVAIRE RÉSISTANT AU PLATINE

    BIONTECH SE [DE] · Granted Mar 19, 2026 · Expires Mar 14, 2046

    granted
  3. US 12427173

    Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies

    Biomed Valley Discoveries, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  4. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  5. AR 133055

    DOMINIOS VARIABLES ÚNICOS DE INMUNOGLOBULINA DIRIGIDOS A PD-L1

    ABLYNX NV [BE] · Granted Aug 20, 2025 · Expires Aug 15, 2045

    granted
  6. US 12391734

    PD-1 homing endonuclease variants, compositions, and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  7. US 12351633

    PD-1 and PD-L1 binding agents

    Orionis Biosciences, Inc · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  8. US 12338269

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Medicenna Therapeutics Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  9. US 12325747

    Human PD-L1 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  10. US 12286483

    Method of treating cancer using CD137 antibodies and PD-1 antagonists

    Compass Therapeutics LLC · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  11. TW 202515903

    Anti-PD-1-based treatment before and after surgery

    BEIGENE SWITZERLAND GMBH [CH] · Granted Apr 16, 2025 · Expires Apr 11, 2045

    granted
  12. US 12269886

    Tetravalent bispecific antibody against PD-1 and PD-L1

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  13. WO 2025040080

    TRAITEMENT DU CANCER DE L'OESOPHAGE PAR ANTI-LAG3, ANTI-PD-1 ET CHIMIOTHÉRAPIE

    BEIGENE SWITZERLAND GMBH [CH] · Granted Feb 27, 2025 · Expires Feb 22, 2045

    granted
  14. US 12187799

    Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor

    The Board of Regents of the University of Texas System · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  15. US 12168688

    Antibodies and variants thereof against PD-L1

    Nanjing Legend Biotech Co., Ltd · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  16. US 12134648

    Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor

    The Board of Regents of the University of Texas System · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  17. US 12089575

    Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  18. US 12053534

    Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  19. US 12054556

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  20. US 12054557

    Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  21. US 12023355

    Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof

    Iovance Biotherapeutics, Inc. · Granted Jul 2, 2024 · Expires Jun 27, 2044

    granted
  22. US 12018015

    Methods and compositions for targeting PD-L1

    Aligos Therapeutics, Inc. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  23. US 11993655

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Granted May 28, 2024 · Expires May 23, 2044

    granted
  24. US 11981736

    Antibodies specific to glycosylated PD-1 and methods of use thereof

    The Board of Regents of the University of Texas System · Granted May 14, 2024 · Expires May 9, 2044

    granted